Prescription drug coverage and copay tiers; authorization for brand drugs when generics exist
Customize your policy alerts
Sign up for all Health-New-England policy alerts
Know when Health-New-England releases new policies or updates existing guidance.
Monitor payer policy activity
Defines retail and mail-order copays, deductible application, and tier definitions for prescription drugs under the 2025 Pharmacy Benefit for HMO Silver 2000 HDHP SG; affects members and prescribing providers in the plan.
No material clinical or coverage changes in this revision.
Coverage Criteria
Authorization for Brand when Generic Exists
Covered when ALL of the following are met
Medical necessity examples include, but are not limited to: inadequate response or allergic reaction to the generic(s) and failure of alternatives in the drug class.
Brand name drugs that have FDA‑approved generic equivalents are not covered at brand tier unless medical necessity is demonstrated. Health New England will cover a brand drug in these circumstances only when the prescriber submits a drug request form and provides supporting documentation that meets the plan’s medical necessity requirements (for example, inadequate response or allergic reaction to the generic(s) or failure of alternatives in the drug class).
Provider Actions and Requirements
Prior authorization and documentation required for brand when generic is available
Prior authorization is required when a prescriber requests coverage of a brand‑name drug that has an FDA‑approved generic equivalent. Providers must submit a completed drug request form and fax supporting documentation of medical necessity to Health New England for review.
- Medical necessity examples: inadequate response to the generic(s), allergic reaction to the generic(s), or other clinical reasons why the generic is unsuitable.
- Step/Alternative requirement: Coverage of brand drugs generally requires failure of appropriate alternatives in the drug class (i.e., attempt and inadequate response to generics or other formulary alternatives) before a brand product will be approved.
- Documentation: Include clinical notes, prior treatment history, allergy information, and any relevant lab or diagnostic results to support the need for the brand drug.
- How to submit: Complete the Health New England drug request form and fax with supporting documentation for review.
- Denial risk: Lack of documentation showing medical necessity or failure to try formulary/generic alternatives may result in denial of the brand request.
Step / Alternative requirement
Providers must document failure of alternatives or contraindications to generics as part of the medical necessity justification. This functions as a step/alternative requirement — before a brand non‑formulary drug will be approved, the member must have tried and had an inadequate response to, or intolerance of, appropriate generic or formulary alternatives unless there is a documented contraindication.
- Specify which alternatives were tried, dates of therapy, doses, and clinical outcomes.
- If an alternative was not used due to contraindication or intolerance, provide detailed clinical rationale and supporting records.
Documentation for brand non‑formulary requests
When requesting coverage for a brand non‑formulary drug, providers must submit the drug request form and fax supporting documentation demonstrating medical necessity. Incomplete submissions or missing supporting documentation (e.g., lack of treatment history, missing allergy documentation) increase the likelihood of denial and will delay review.
- Required items to fax: completed drug request form, clinical notes documenting prior trials and outcomes, allergy history, and any pertinent diagnostics.
- Operational note: Retain copies of all submitted documentation in the patient record in case of audit or appeal.
Medical necessity required for brand when generic exists
Brand name drugs that have FDA‑approved generic equivalents are covered only when medical necessity is demonstrated. Absence of adequate documentation of medical necessity (including failure of generics or documented contraindication) is a valid basis for denial.
- Medical necessity may include inadequate response or allergic reaction to the generic(s), and failure of alternatives in the drug class.
- Pharmacists in Massachusetts are required to substitute generics unless the prescriber writes 'no substitution' on the prescription; include justification if brand prescribing seeks to override substitution laws.
Definitions (Tiers)
Step Therapy Requirements
| Step | Requirement | Failure criteria |
|---|---|---|
| 1 | Documentation of failure or intolerance to generics/alternatives required for brand approval. Prescriber must submit a drug request form with documentation of medical necessity for a brand name drug when an FDA‑approved generic equivalent exists. | Inadequate response or allergic reaction to the generic(s); failure of alternatives in the drug class. |
Background
Not applicable — this document defines benefit design and administrative coverage rules for prescription drug tiers and prior authorization procedures rather than providing clinical treatment guidance.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.